MDxHealth SA (NASDAQ:MDXH) Sees Significant Increase in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 31,100 shares, a growth of 133.8% from the February 13th total of 13,300 shares. Based on an average daily volume of 113,500 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the shares of the stock are sold short.

MDxHealth Stock Performance

NASDAQ MDXH opened at $1.48 on Friday. MDxHealth has a 1 year low of $1.35 and a 1 year high of $3.50. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. The stock has a market capitalization of $69.99 million, a PE ratio of -0.97 and a beta of 1.37. The company’s 50 day simple moving average is $1.85 and its two-hundred day simple moving average is $2.08.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. The business had revenue of $24.74 million for the quarter, compared to analysts’ expectations of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. Analysts predict that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of MDxHealth

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC purchased a new stake in shares of MDxHealth during the 4th quarter valued at $25,000. Oppenheimer & Co. Inc. raised its position in shares of MDxHealth by 100.0% during the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock valued at $47,000 after buying an additional 10,000 shares in the last quarter. FAS Wealth Partners Inc. raised its position in shares of MDxHealth by 49.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock valued at $58,000 after buying an additional 8,100 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of MDxHealth during the 4th quarter valued at $63,000. Finally, Delta Investment Management LLC bought a new position in shares of MDxHealth during the 4th quarter valued at $81,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.